Cancer Clinical Trials May Benefit Patients Who Typically Don't Qualify

Many patients with cancer do not qualify for clinical trials because of comorbidities or other health problems. However, a recent study found that many of these patients can actually benefit from trials.
BY ELLIE LEICK
PUBLISHED: JANUARY 09, 2017
Clinical trials are imperative in helping find treatments for patients with cancer. However, many patients with poor prognoses or other comorbidities often get turned away from participating because they are deemed “too sick” according to eligibility criteria, such as having existing medical illnesses. These patients who are being turned away are the people who could potentially benefit the most from trials.
 
A recent novel study at The University of Texas MD Anderson Cancer Center showed patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) responded well and were safely treated in a clinical trial setting, though they would not typically qualify.
 
According to Guillermo Garcia-Manero, M.D., Professor of Leukemia at the MD Anderson Cancer Center, who led the study, the most common reasons why patients are excluded from clinical trials are their poor kidney function, poor liver function, malignancy and life expectancy. However, in Garcia-Manero’s opinion, there is often no clinical reason for patients with these comorbidities to be excluded.
 
“Clinical trials are meant to protect the patient,” Garcia-Manero said. “However, the eligibility criteria in place protects the study rather than the patient.”
 
The study followed 109 patients with AML and MDS who were at least 17 years old and had not previously received treatment for AML or MDS. All participants had poor performance, poor renal or hepatic function or any other active systemic disorder such as cancer.
 


Talk about this article with other patients, caregivers, and advocates in the Leukemia CURE discussion group.
x-button
Special Feature
Share Your Art
Related Articles
The Logistics of Multigene Panel Testing in Breast Cancer
Generally, health insurance covers the cost of genetic testing recommended by a physician. However, some patients who had BRCA testing in the past have had trouble getting reimbursed for a follow-up panel test. The outof- pocket cost for a single panel test can be up to $5,000, although lower-cost tests are available.
Young Patients With Cancer Don't Always Get the Info They Need
When treated for cancer, young patients don’t always get the information they need from doctors.
Immunotherapy Offers New Optimism for Patients With Merkel Cell Carcinoma
Although chemotherapy has been used to treat patients with Merkel cell carcinoma, immunotherapy agents show great promise, according to findings presented at the 2017 World Congress of Melanoma.
Related Videos
Preserving Eyebrows During Chemotherapy Treatment
Renata Marie Vestevich, founder and developer of Essential Eyebrow Solution (EES), discusses how this topical solution may be able to help patients keep their eyebrow hair while undergoing chemotherapy.
Does Age Affect Cancer Genomics?
Garrett Frampton, associate director of Cancer Genomics at Foundation Medicine, discusses recent research about genetic mutations that are more common in certain age groups.  
Facing Advanced Cancer's Struggles With CALM
Gary Rodin, M.D., head of the Department of Supportive Care at Princess Margaret Cancer Centre, in Toronto, Canada, discusses CALM, an intervention designed to help patients with advanced-stage cancer cope and talk about their concerns.
x
//For side ad protocol